EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis

Marc-André Limoges, Audrey Lortie, Élodie Demontier, Akouavi Julite Irmine Quenum, Félix Lessard, Zacharie Drouin, Nathalie Carrier, Leopold Mbous Nguimbus, Marie-Claude Beaulieu, Gilles Boire iD, Alain Piché, Hugues Allard-Chamard und 2 weitere

Journal of Leukocyte Biology · 2023

DOI: 10.1093/jleuko/qiad086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2023. Verfasst von Marc-André Limoges und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Cell Biology, Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, …. Hauptthemen laut MEDLINE: COVID-19, Arthritis, Rheumatoid. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Clinician Scientist Fellowship Program of the Department of Medicine, Faculty of Medicine, Sherbrooke University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our objective was to characterize T and B cell responses to vaccination with SARS-CoV-2 antigens in immunocompromised rheumatoid arthritis (RA) patients. In 22 RA patients, clinical and biological variables were analyzed before and 4 weeks after each of 3 messenger RNA (mRNA) vaccine doses and compared with unmatched healthy individuals. Sequentially sampled peripheral blood mononuclear cells and sera were collected to determine immune profiles and to analyze the T cell response to a spike peptide pool and B cell specificity to the receptor-binding domain (RBD). Anti-spike antibodies were detectable in 6 of 22 RA patients after 1 dose of vaccine with increasing titers after each booster dose, although the overall response was lower compared with that in healthy control individuals. Responding patients after the first dose were more likely to have RA antibodies and a higher baseline proportion of circulating follicular B cells. In RA patients, the mRNA vaccine elicited a robust CD4+ T response to a spike peptide pool following the first and second doses. Consistent with the serologies, RBD-specific B cells exhibited a modest increase after the first dose and the second dose resulted in marked increases only in a fraction of the RA patients to both ancestral and omicron RBD. Our results highlight the importance of multidose COVID-19 vaccination in RA patients to develop a protective humoral response. However, these patients rapidly develop specific T CD4+ responses, despite delayed B cell responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Arthritis, RheumatoidHumansCOVID-19 VaccinesSARS-CoV-2Leukocytes, MononuclearRNA, MessengerImmunityAntibodies, ViralVaccinationmRNA Vaccines

Stichwörter der Autor:innen

PBMC flow cytometrySARS-CoV-2anti-spike serologyimmunizationin vitro B and T immune responserheumatoid arthritis

Substanzen

COVID-19 VaccinesRNA, MessengerAntibodies, ViralmRNA Vaccines

Autor:innen und Institutionen

  • Department of Immunology and Cell Biology, Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4.
  • Division of Rheumatology, Department of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4.
  • Department of Family and Emergency Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4.
  • Division of Infectious Diseases, Department of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4.
  • Department of Microbiology and Infectious Diseases, Université de Sherbrooke, 3001, 12th avenue N, Sherbrooke, PQ, Canada, J1H5N4.

ORCID-Profile: Gilles Boire

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Clinician Scientist Fellowship Program of the Department of Medicine, Faculty of Medicine, Sherbrooke University
  • Faculty of Medicine, Sherbrooke University

Zitieren

APA

Limoges, M. A., Lortie, A., Demontier, É., Quenum, A. J. I., Lessard, F., Drouin, Z., Carrier, N., Nguimbus, L. M., Beaulieu, M. C., Boire, G., Piché, A., Allard-Chamard, H., Ramanathan, S., & Roux, S. (2023). SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiad086

Vancouver

Limoges MA, Lortie A, Demontier É, Quenum AJI, Lessard F, Drouin Z, et al. SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis. Journal of Leukocyte Biology. 2023. doi:10.1093/jleuko/qiad086

BibTeX
@article{Limoges2023,
  author = {Limoges, Marc-André and Lortie, Audrey and Demontier, Élodie and Quenum, Akouavi Julite Irmine and Lessard, Félix and Drouin, Zacharie and Carrier, Nathalie and Nguimbus, Leopold Mbous and Beaulieu, Marie-Claude and Boire, Gilles and Piché, Alain and Allard-Chamard, Hugues and Ramanathan, Sheela and Roux, Sophie},
  title = {SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis},
  journal = {Journal of Leukocyte Biology},
  year = {2023},
  doi = {10.1093/jleuko/qiad086}
}
Kostenlos starten →